Unlock the power of CGP testing with an enhanced workflow with HRD using the AVENIO Tumor Tissue CGP Kit V2

Precision oncology is rapidly evolving, often driving clinical trials through a biomarker-centric approach and identifying new treatment targets. The significance of genomic signatures, such as Homologous Recombination Deficiency (HRD), has grown considerably, necessitating ongoing advancements in assay and bioinformatics development. Roche and Foundation Medicine have introduced the updated AVENIO Tumor Tissue CGP Kit V2* (Research Use Only), featuring improved workflows and bioinformatics, shorter wet-lab procedures, reduced sequencing costs, the addition of emerging oncology genes, enhanced variant calling algorithms, and a new pan-cancer HRD signature developed by Foundation Medicine. The updated AVENIO Tumor Tissue CGP Kit V2 maintains robust performance while enabling laboratories to expand their sequencing research capabilities.
* For Research Use Only.